Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

NCT01394952 on ClinicalTrials.gov · last registry update 2019-10-08

An unusually large phase 3: 9,901 participants, more than double the 424 typical for the stage. Completed 21 August 2018. dulaglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 9,901
Started: 2011-07-22
Primary completion: 2018-08-21 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

Conditions studied

Cardiovascular Disease · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.